Summit Therapeutics highlights potential of gonorrhoea treatment at key conference

Writer, Stock Market Wire
Wednesday, July 17, 2019 - 13:08

Summit Therapeutics said that it had highlighted the potential of its pre-clinical new class antibiotic to treat all gonorrhoea, including multi-drug resistant strains, at the STI & HIV World Congress in Vancouver, Canada.

'The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease,' said R&D president David Roblin

'As shown by the pre-clinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains.'

'Further, there is a clear need for new gonorrhoea treatment options that would allow ceftriaxone to be reserved for the multitude of other serious infections that rely on its potency.'

At 1:08pm: (LON:SUMM) Summit Therapeutics PLC share price was +0.25p at 24.25p


Related content

Summit Therapeutics CEO Glyn Edwards to present at San Francisco conference

Summit Therapeutics said chief executive Glyn Edwards would present at an industry conference in San Francisco.

Edwards would present at the 2019 BIO Investor Forum...

Wed, 16/10/2019 - 13:11


Summit Therapeutics losses deepen on higher R&D spend

Pharmaceutical company Summit Therapeutics posted a deeper second-quarter loss amid a rise in R&D spending.

Pre-tax losses for the three months through September amounted to...

Fri, 11/10/2019 - 13:52


Summit Therapeutics books first-quarter loss on higher R&D spend

Antibiotics developer Summit Therapeutics booked a first-quarter loss as it ramped up R&D spending.

Pre-tax losses for the three months through March amounted to...

Wed, 12/06/2019 - 13:09


Summit Therapeutics presents antibiotic concept data at Amsterdman conference

Summit Therapeutics said it had presented proof of concept data for a series of new antibiotics at a conference in Amsterdam.

The data was presented...

Mon, 15/04/2019 - 08:06


Summit Therapeutics swings to profit

Summit Therapeutics swung to an annual profit as it continued to develop its antibiotic portfolio.

Pre-tax profit for the year through amounted to £5.0m, compared...

Wed, 27/03/2019 - 13:22